Shooting for $100M IPO, Schrödinger takes the wraps off its five internal drugs and discloses deal details

Just before last year’s JP Morgan confab kicked off, Schrödinger unveiled its first venture round featuring institutional investors before later closing the Series E at $110 million. This time around, the computational drug discovery experts are inserting themselves into the queue at the Nasdaq, gunning for a $100 million IPO.